Dr. Baldo has more than 20 years of clinical, product development and operational experience, and will report to Freenome chief executive officer, Mike Nolan.
In his role, Dr. Baldo oversees all aspects of Freenome’s clinical development, medical and scientific affairs, quality and regulatory teams. His initial focus will be on Freenome’s expanding capabilities beyond colorectal cancer (CRC), including launching additional clinical and real world data (RWD) studies to test the platform for multiple cancers.
Most recently, Dr. Baldo served as chief medical officer of Adaptive Biotechnologies where he led clinical development, quality, regulatory and health policy to support a portfolio of clinical diagnostics and therapeutics. Previously, he held numerous roles with the Roche Group and its affiliates, including as senior vice president and head of U.S. medical affairs at Genentech. Lance holds an MD from the University of Connecticut School of Medicine and a BA in Biology from Johns Hopkins University.